CHPA expresses disappointment in the recent NDAC recommendation and encourages FDA to consider the total weight of evidence before making any regulatory changes.
CHPA's most current statement on the recent meeting of the FDA Nonprescription Advisory Committee (NDAC) to evaluate the efficacy of oral phenylephrine (PE).
A recent national survey of adults conducted by the Bullfinch Group for CHPA further sheds light on consumer awareness, experiences, and perceptions of PE.
CHPA released the below statement today following the U.S. Food and Drug Administration’s announcement that it will postpone its previously scheduled April 12 Nonprescription Drugs Advisory Committee meeting to reconsider the efficacy of oral phenylephrine.
A newly published article in the medical journal Pediatrics concludes that over-the-counter (OTC) cough and cold medicines for children are safe when used and stored as directed.
This Proposed Safety Administrative Order addresses the GRASE status of codeine, codeine phosphate, and codeine sulfate as antitussive active ingredients.
